Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CD34t CAR T-cell Therapy in Relapsed/Refractory B-Cell NHL and CLL/SLL
NCT05702853Phase 2Recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Nov 2023
- Primary completion
- Nov 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19-CD34t metabolically programmed CAR transduced T-cells in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Medical University of South Carolina. Started Nov 2023; status: recruiting.
02
Drugs
CD19-CD34t metabolically programmed CAR transduced T-cells
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05702853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05702853.